1312686-23-9

Basic information

• Product Name: 6-acetyl-4-chloro-2-cyano-3-methylphenyl trifluoromethanesulfonate
• Synonyms: 6-acetyl-4-chloro-2-cyano-3-methylphenyl trifluoromethanesulfonate
• CAS NO: 1312686-23-9
• Molecular Weight: 341.695
• Mol File: 1312686-23-9.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 6-acetyl-4-chloro-2-cyano-3-methylphenyl trifluoromethanesulfonate(CAS DataBase Reference)
• NIST Chemistry Reference: 6-acetyl-4-chloro-2-cyano-3-methylphenyl trifluoromethanesulfonate(1312686-23-9)
• EPA Substance Registry System: 6-acetyl-4-chloro-2-cyano-3-methylphenyl trifluoromethanesulfonate(1312686-23-9)

Safety Data

• Hazardous Substances Data: 1312686-23-9(Hazardous Substances Data)

Upstream product

• 1312686-22-8 3-acetyl-5-chloro-2-hydroxy-6-methylbenzonitrile 
• 1025373-45-8 trifluoromethanesulfonic acid anhydride 
• 1382994-99-1 1-(3-bromo-5-chloro-2-methoxy-4-methylphenyl)ethanone 
• 28480-70-8 5'-chloro-2'-hydroxy-4'-methyl acetophenone 
• 358-23-6 trifluoromethylsulfonic anhydride 

Downstream Products

• 1312686-28-4 1-[5-chloro-8-(3-fluorophenyl)isoquinolin-7-yl]ethanol 
• 1312686-29-5 7-(1-azidoethyl)-5-chloro-8-(3-fluorophenyl)isoquinoline 
• 1312686-30-8 1-[5-chloro-8-(3-fluorophenyl)isoquinolin-7-yl]ethyl methanesulfonate 
• 1312686-31-9 1-[5-chloro-8-(3-fluorophenyl)isoquinolin-7-yl]ethanamine 
• 1382992-83-7 4-chloro-3'-fluoro-3-methyl-6-{1-[(9H-purin-6-yl)amino]ethyl}-[1,1'-biphenyl]-2-carbonitrile 
• 1382992-90-6 N-{1-[4-chloro-3'-fluoro-5-methyl-6-(1H-tetrazol-5-yl)biphenyl-2-yl]ethyl}-9H-purin-6-amine 
• 1382993-01-2 4-Chloro-3',5'-difluoro-3-methyl-6-[1-(9H-purin-6-ylamino)ethyl]biphenyl-2-carboxamide 
• 1382992-84-8 4-Chloro-3'-fluoro-3-methyl-6-[1-(9H-purin-6-ylamino)ethyl]biphenyl-2-carboxamide 

Relevant articles and documents

INCB050465 (Parsaclisib), a Novel Next-Generation Inhibitor of Phosphoinositide 3-Kinase Delta (PI3Kδ)

A medicinal chemistry effort focused on identifying a structurally diverse candidate for phosphoinositide 3-kinase delta (PI3Kδ) led to the discovery of clinical candidate INCB050465 (20, parsaclisib). The unique structure of 20 contains a pyrazolopyrimidine hinge-binder in place of a purine motif that is present in other PI3Kδinhibitors, such as idelalisib (1), duvelisib (2), and INCB040093 (3, dezapelisib). Parsaclisib (20) is a potent and highly selective inhibitor of PI3Kδwith drug-like ADME properties that exhibited an excellent in vivo profile as demonstrated through pharmacokinetic studies in rats, dogs, and monkeys and through pharmacodynamic and efficacy studies in a mouse Pfeiffer xenograft model.

HETEROCYCLYLAMINES AS PI3K INHIBITORS

The present invention provides heterocyclylamine derivatives of Formula I: wherein the variables are defined herein, that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.

SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS

The present invention provides fused aryl and heteroaryl derivatives of Formula I that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases